scholarly journals Crown disease with extrainterinal manifestations in the form of granulematous alveolitis

2022 ◽  
pp. 90-96
Author(s):  
P. N. Barlamov ◽  
Yu. I. Tretyakova ◽  
V. G. Zhelobov ◽  
O. V. Khlynova
Keyword(s):  
Clinical Manifestations ◽  
Lung Abscess ◽  
Genetically Engineered ◽  
Therapeutic Effects ◽  
Lung Lesions ◽  
Tuberculous Lesion ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Potential Risks ◽  
Clinical Description

Objective: To present a clinical description of the observation of a patient with Crohn’s disease (CD) with extraintestinal manifestations in the form of granulomatous alveolitis.Materials and Methods: A brief review of the literature on the current understanding of the prevalence and clinical manifestations of lung lesions in inflammatory bowel diseases (IBD) and CD, as well as a description of a patient with this pathology with the results of autopsy is presented.Results: The rare presence of granulomatous lung lesions in a patient with CD was proved.Conclusion: Difficulties in the differential diagnosis and treatment of CD lung lesions are shown. In particular, suspicion of tuberculous lesion, lung abscess creates potential risks of generalization of the process when using such therapeutic effects as glucocorticosteroids, cytostatics, immunosuppressants, biological genetically engineered drugs and active surgical intervention. The authors hope that the described observation will alert doctors in terms of possible systemic pulmonary lesions in CD.

scholarly journals The diagnostic and prognostic value of serological markers of inflammatory bowel diseases (a literature review)

2020 ◽  
Vol 48 (6) ◽  
pp. 364-374
Author(s):  
D. А. Kuznetsova ◽  
S. V. Lapin ◽  
O. B. Shchukina
Keyword(s):  
Differential Diagnosis ◽  
Prognostic Significance ◽  
Immunological Tolerance ◽  
Genetically Engineered ◽  
Diagnostic Methods ◽  
Serological Markers ◽  
Diagnosis And Prognosis ◽  
Bowel Diseases ◽  
Risk Of Progression ◽  
Inflammatory Bowel

The diagnosis of inflammatory bowel disease (IBD) is based on a combination of clinical, endoscopic, histological, radiological and laboratory methods. However, conventional diagnostic methods are not always sufficiently informative in IBD, especially in the case of unclassified colitis, which necessitates the extension of standard diagnostic approaches. Currently, there is an actively search for non-invasive serological markers for early and differential diagnosis of IBD and for the assessment of activity and prognosis of Crohn's disease (CD) and ulcerative colitis (UC). Among the most interesting serological markers are anti-Saccharomyces cerevisiae antibodies (ASCA), anti-neutrophil cytoplasmic antibodies (ANCA), goblet cells antibodies (GAB) and pancreatic autoantibodies (PAB). The aim of this review is to assess the diagnostic and prognostic significance of ASCA, ANCA, GAB, PAB in CD and UC. The paper presents the summary of the data on the role of ASCA, ANCA, GAB and PAB in abnormalities of the immunological tolerance mechanisms to intestinal microflora and intestinal permeability in IBD. We discuss the results of the studies on the associations of ASCA with a complicated CD phenotype, its response to genetically engineered biological therapies, and the need for surgical intervention. The article describes the data on the association of ANCA to the risk of progression of left-sided UC to widespread (total) colon lesions resistant to hormonal therapy, and that of antibodies to DNA-lactoferrin complexes and proteinase 3 to primary sclerosing cholangitis. It has been noted that PAB may be a prognostic marker for ileocolitis, perianal lesions, extraintestinal manifestations and complicated CD, and GAB a  predictor of total UC with chronic persistent course. It should be emphasized that combined determination of ASCA, ANCA, GAB and PAB is highly informative, compared to the isolated detection of autoantibodies, for the differential diagnosis and prognosis of CD and UC.

scholarly journals Nanostructured Chitosan-Based Biomaterials for Sustained and Colon-Specific Resveratrol Release

2019 ◽  
Vol 20 (2) ◽  
pp. 398 ◽  
Author(s):  
Nieves Iglesias ◽  
Elsa Galbis ◽  
M. Díaz-Blanco ◽  
Ricardo Lucas ◽  
Elena Benito ◽  
...  
Keyword(s):  
Release Kinetics ◽  
Therapeutic Effects ◽  
Independent Variables ◽  
Bowel Diseases ◽  
Microscopic Features ◽  
Inflammatory Bowel ◽  
Kinetics Of ◽  
Colonic Release ◽  
Two Independent Variables ◽  
Polymer Ratio

In the present work, we demonstrate the preparation of chitosan-based composites as vehicles of the natural occurring multi-drug resveratrol (RES). Such systems are endowed with potential therapeutic effects on inflammatory bowel diseases (IBD), such as Crohn’s disease (CD) and ulcerative colitis, through the sustained colonic release of RES from long-lasting mucoadhesive drug depots. The loading of RES into nanoparticles (NPs) was optimized regarding two independent variables: RES/polymer ratio, and temperature. Twenty experiments were carried out and a Box–Behnken experimental design was used to evaluate the significance of these independent variables related to encapsulation efficiency (EE). The enhanced RES EE values were achieved in 24 h at 39 °C and at RES/polymer ratio of 0.75:1 w/w. Sizes and polydispersities of the optimized NPs were studied by dynamic light scattering (DLS). Chitosan (CTS) dispersions containing the RES-loaded NPs were ionically gelled with tricarballylic acid to yield CTS-NPs composites. Macro- and microscopic features (morphology and porosity studied by SEM and spreadability), thermal stability (studied by TGA), and release kinetics of the RES-loaded CTS-NPs were investigated. Release patterns in simulated colon conditions for 48 h displayed significant differences between the NPs (final cumulative drug release: 79–81%), and the CTS-NPs composites (29–34%).

scholarly journals The onset of psoriasis during the treatment of inflammatory bowel diseases with infliximab: should biological therapy be suspended?

2012 ◽  
Vol 49 (2) ◽  
pp. 172-176 ◽  
Author(s):  
Rafael Denadai ◽  
Fábio Vieira Teixeira ◽  
Rogério Saad-Hossne
Keyword(s):  
Clinical Manifestations ◽  
Infliximab Therapy ◽  
Inclusion Criteria ◽  
Therapeutic Approaches ◽  
Plaque Type ◽  
Bowel Diseases ◽  
History Of ◽  
Cutaneous Reactions ◽  
Inflammatory Bowel ◽  
Psoriatic Lesions

CONTEXT: Several paradoxical cases of infliximab-induced or-exacerbated psoriatic lesions have been described in the recent years. There is disagreement regarding the need to discontinue infliximab in order to achieve the resolution of these adverse cutaneous reactions specifically in inflammatory bowel disease (IBD) patients. OBJECTIVE: To systematically review the literature to collect information on IBD patients that showed this adverse cutaneous reaction, focusing mainly on the therapeutic approach. METHODS: A systematic literature review was performed utilizing Medline, Embase, SciELO and Lilacs databases. Published studies were identified, reviewed and the data were extracted. RESULTS: Thirty-four studies (69 IBD patients) met inclusion criteria for review. There was inconsistency in reporting of some clinical and therapeutic aspects. Most patients included had Crohn's disease (89.86%), was female (47.83%), had an average age of 27.11 years, and no reported history of psoriasis (84.05%). The patients developed primarily plaque-type psoriasis (40.58%). There was complete remission of psoriatic lesions in 86.96% of IBD patients, existing differences in the therapeutic approaches; cessation of infliximab therapy led to resolution in 47.83% of cases and 43.48% of patients were able to continue infliximab therapy. CONCLUSION: As increasing numbers of IBD patients with psoriasis induced or exacerbated by infliximab, physicians should be aware of its clinical manifestations so that appropriate diagnosis and treatment are properly established. The decision whether to continue or discontinue infliximab should be individualized.

scholarly journals Potential Application of Probiotics in the Prevention and Treatment of Inflammatory Bowel Diseases

Ulcers ◽  
2011 ◽  
Vol 2011 ◽  
pp. 1-13 ◽  
Author(s):  
Silvina del Carmen ◽  
Alejandra de Moreno de LeBlanc ◽  
Anderson Miyoshi ◽  
Clarissa Santos Rocha ◽  
Vasco Azevedo ◽  
...  
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Antioxidant Properties ◽  
Genetically Engineered ◽  
Treatment Protocols ◽  
Host Immune Responses ◽  
Beneficial Effects ◽  
Wide Range ◽  
Prevention And Treatment ◽  
Bowel Diseases ◽  
Inflammatory Bowel

Lactic acid bacteria (LAB) represent a heterogeneous group of microorganisms that are naturally present in many foods and possess a wide range of therapeutic properties. The aim of this paper is to present an overview of the current expanding knowledge of the mechanisms by which LAB and other probiotic microorganisms participate in the prevention and treatment of inflammatory bowel diseases. These include changes in the gut microbiota, stimulation of the host immune responses, and reduction of the oxidative stress due to their antioxidant properties. A brief overview of the uses of genetically engineered LAB that produce either antioxidant enzymes (such as catalase and superoxide dismutase) or anti-inflammatory cytokines (such as IL-10) will also be discussed. This paper will show that probiotics should be considered in treatment protocols of IBD since they provide many beneficial effects and can enhance the effectiveness of traditional used medicines.

Apple peel polyphenols: a key player in the prevention and treatment of experimental inflammatory bowel disease

2016 ◽  
Vol 130 (23) ◽  
pp. 2217-2237 ◽  
Author(s):  
Marie-Claude Denis ◽  
Denis Roy ◽  
Pantea Rahmani Yeganeh ◽  
Yves Desjardins ◽  
Thibault Varin ◽  
...  
Keyword(s):  
Fruits And Vegetables ◽  
Intestinal Inflammation ◽  
Therapeutic Effects ◽  
Microbial Composition ◽  
Beneficial Effects ◽  
Apple Peel ◽  
Bowel Diseases ◽  
Clinical Benefits ◽  
Inflammatory Bowel ◽  
Underlying Mechanisms

Diets rich in fruits and vegetables may reduce oxidative stress (OxS) and inflammation via several mechanisms. These beneficial effects may be due to their high polyphenol content. The aims of the present study are to evaluate the preventive and therapeutic aspects of polyphenols in dried apple peel powder (DAPP) on intestinal inflammation while elucidating the underlying mechanisms and clinical benefits. Induction of intestinal inflammation in mice was performed by oral administration of the inflammatory agent dextran sulfate sodium (DSS) at 2.5% for 10 days. Physiological and supraphysiological doses of DAPP (200 and 400 mg/kg/day respectively) were administered by gavage for 10 days pre- and post-DSS treatment. DSS-mediated inflammation caused weight loss, shortening of the colon, dystrophic detachment of the epithelium, and infiltration of mono- and poly-morphonuclear cells in the colon. DSS induced an increase in lipid peroxidation, a down-regulation of antioxidant enzymes, an augmented expression of myeloperoxidase (MPO) and cyclooxygenase-2 (COX-2), an elevated production of prostaglandin E2 (PGE2) and a shift in mucosa-associated microbial composition. However, DAPP normalized most of these abnormalities in preventive or therapeutic situations in addition to lowering inflammatory cytokines while stimulating antioxidant transcription factors and modulating other potential healing pathways. The supraphysiological dose of DAPP in therapeutic situations also improved mitochondrial dysfunction. Relative abundance of Peptostreptococcaceae and Enterobacteriaceae bacteria was slightly decreased in DAPP-treated mice. In conclusion, DAPP exhibits powerful antioxidant and anti-inflammatory action in the intestine and is associated with the regulation of cellular signalling pathways and changes in microbiota composition. Evaluation of preventive and therapeutic effects of DAPP may be clinically feasible in individuals with intestinal inflammatory bowel diseases.

scholarly journals Oral Feeding of ProbioticBifidobacterium infantis: Colonic Morphological Changes in Rat Model of TNBS-Induced Colitis

Scientifica ◽  
2016 ◽  
Vol 2016 ◽  
pp. 1-11 ◽  
Author(s):  
Najma H. Javed ◽  
Musaad B. Alsahly ◽  
Jagdish Khubchandani
Keyword(s):  
Morphological Changes ◽  
Bacterial Flora ◽  
Mucosal Damage ◽  
Oral Feeding ◽  
Chronic Inflammatory Bowel Disease ◽  
Unknown Etiology ◽  
Therapeutic Effects ◽  
Distilled Water ◽  
Bowel Diseases ◽  
Inflammatory Bowel

Ulcerative colitis (UC) is a chronic inflammatory bowel disease of unknown etiology. It has been proposed that modifying the bacterial flora in intestine with probiotics may decrease the inflammatory process and prevent relapses in UC. We investigated the possible protective and therapeutic effects of a single strand of probiotic,Bifidobacterium infantis(BI), on colonic inflammation, in rats with regular feedings. Two groups of Lewis rats were prepared (n=8). The first group was the control, sham-fed group (n=4). The other group was the experimental BI-fed group (n=4). Colitis was induced in both groups by intrarectal administration of TNBS under light anesthesia. The sham-fed colitis induced groups received a daily oral gavage feeding of 1.0 mL distilled water, whereas theB. infantis-fed group received 0.205 g ofB. infantisdissolved in 1.0 mL distilled water daily. The change in body weight and food and water intake was recorded over the course of each study and analyzed. The rats were euthanized and tissues from the descending colon were harvested and analyzed microscopically and histologically. Results of our study indicated significant reduction in inflammation, mucosal damage, and preservation of goblet cells, as compared to the control animals. Modulation of gastrointestinal (GI) flora suggests a promising field in developing strategies for prevention and treatment of inflammatory bowel diseases by dietary modifications.

scholarly journals The Role of Thrombospondin 1 on Intestinal Inflammation and Carcinogenesis

2008 ◽  
Vol 3 ◽  
pp. BMI.S630 ◽  
Author(s):  
Linda S. Gutierrez
Keyword(s):  
Colorectal Adenocarcinoma ◽  
Intestinal Inflammation ◽  
The United States ◽  
Colorectal Carcinogenesis ◽  
Therapeutic Effects ◽  
Thrombospondin 1 ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Novel Therapeutic

Crohn's disease and ulcerative colitis are inflammatory bowel diseases (IBD) quite common in the United States and other Western countries. Patients suffering IBD are at greater risk of developing colorectal adenocarcinoma than the general population. Both, the adenoma-carcinoma and the inflammation-carcinogenesis processes are characterized by active angiogenesis. Recent studies also have shown that anti-angiogenesis might be a novel therapeutic approach for IBD. Thrombospondin 1 (TSP1) is an extracellular protein well known for its anti-angiogenic properties. TSP1 also has key functions in inflammation, which is assumed to be the primary cause for carcinogenesis in IBD. This review is focused on the role of TSP1 in colorectal carcinogenesis. The therapeutic effects of TSP derived-peptides on inhibiting the inflammation-carcinogenesis progression are also discussed.

GLUT5 is a determinant of dietary fructose-mediated exacerbation of experimental colitis

2021 ◽  
Author(s):  
Srijani Basu ◽  
Catherine Liu ◽  
Xi Kathy Zhou ◽  
Ryohei Nishiguchi ◽  
Taehoon Ha ◽  
...  
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Experimental Colitis ◽  
Fecal Microbiota ◽  
Genetically Engineered ◽  
Western Diet ◽  
High Fructose ◽  
Genetically Engineered Mice ◽  
Dietary Fructose ◽  
Bowel Diseases ◽  
Inflammatory Bowel

The western diet has been suggested to contribute to the rising incidence of Inflammatory Bowel Diseases. This has led to the hypothesis that fructose, a component of the western diet, could play a role in the pathogenesis of Inflammatory Bowel Diseases. A high fructose diet is known to exacerbate experimental colitis. This study tested whether the expression of GLUT5, the fructose transporter, is a determinant of the severity of experimental colitis during elevated fructose consumption and whether ileal inflammation is associated with altered GLUT5 expression in Crohn's Disease. Studies in genetically engineered mice showed that in comparison to Glut5+/+ mice, feeding a 15 kcal% fructose diet to Glut5-/- mice led to worse dextran sodium sulfate (DSS)-induced colitis. This effect was associated with elevated levels of colonic fructose and a shift in the fecal microbiota in Glut5-/- mice. Importantly, treatment with broad-spectrum antibiotics protected against the worsening of colitis mediated by dietary fructose in Glut5-/- mice. Gene expression analysis revealed that GLUT5 levels are reduced in patients with Crohn's ileitis. Moreover, levels of GLUT5 negatively correlated with levels of pro-inflammatory mediators. Collectively, these results demonstrate that dietary constituent (fructose)-host gene (GLUT5) interactions can shape the colonic microbiota thereby impacting the severity of colitis.

scholarly journals Psoriasis and inflammatory bowel diseases: pathogenetic pathways and the choice of biologic therapy (a literature review)

2019 ◽  
Vol 47 (6) ◽  
pp. 568-578 ◽  
Author(s):  
L. S. Kruglova ◽  
A. N. Lvov ◽  
A. V. Kagramanova ◽  
O. V. Knyazev
Keyword(s):  
Ulcerative Colitis ◽  
Crohn’S Disease ◽  
Psoriatic Arthritis ◽  
Crohn's Disease ◽  
Genetically Engineered ◽  
Evidence Level ◽  
Frequent Administration ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Effector Cytokines

Psoriasis and inflammatory bowel disease (IBD) are multifactorial chronic immuno-inflammatory potentially disabling disorders with similar genetic factors and immunological pathways, in particular, genetic polymorphisms of IL-23R, which determines the signal IL-12/23-mediated pathway of immunopathogenesis. The emergence of genetically engineered biological agents has changed the prognosis for both psoriasis and IBD. The intersection of the therapeutic spectrum in psoriasis and IBD is a very important point when choosing the management strategy for these patients. Infliximab and adalimumab are effective in the treatment of psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis (evidence level 1A). Ustekinumab demonstrates effectiveness in the treatment of psoriasis, psoriatic arthritis (evidence level 1A) and Crohn's disease (evidence level 1B). Etanercept and secukinumab have been shown to be effective against psoriasis, psoriatic arthritis (evidence level 1A) and ineffective and even associated with exacerbation risk in Crohn's disease and ulcerative colitis. Inhibition of regulatory cytokines IL-12/23 also has a number of advantages compared to the blockade of effector cytokines (TNF-α, IL-17) due to potentially long-term and stable treatment results and less frequent administration.

Sign in / Sign up

Export Citation Format

Share Document